Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context
Background The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. The vaccine will soon be deployed at scale in sub-Saharan Africa. This study aimed to understand the caregiver and community a...
Saved in:
Main Authors: | Jayne Webster, Brian Greenwood, Daniel Chandramohan, Alassane Dicko, Issaka Sagara, Djibrilla Issiaka, Adrian VS Hill, Halimatou Diawara, Fatoumata Koita, Seydou Traoré, Jane Grant, Mehreen Datoo, Mala Sylla, Abdrahmane Boncane Dicko |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | BMJ Global Health |
Online Access: | https://gh.bmj.com/content/10/2/e015524.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
by: Jean Bosco Ouédraogo, et al.
Published: (2023-04-01) -
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
by: M. Sanni Ali, et al.
Published: (2025-02-01) -
Assessing the Acceptability and Feasibility of Five Cycles of Seasonal Malaria Chemoprevention in Côte d’Ivoire
by: Orphée Kangah, et al.
Published: (2024-12-01) -
Impact of seasonal malaria chemoprevention timing on clinical malaria incidence dynamics in the Kedougou region, Senegal
by: Betty Kazanga, et al.
Published: (2025-01-01) -
Hodgkin Lymphoma at the Paediatric Oncology Unit of Gabriel Touré Teaching Hospital, Bamako, Mali: 5-Year Experience
by: B. Togo, et al.
Published: (2011-01-01)